Naproxen sodium/metoclopramide

Drug Profile

Naproxen sodium/metoclopramide

Alternative Names: Metoclopramide/naproxen-sodium; MT 100; Naproxen-sodium/metoclopramide

Latest Information Update: 08 Jul 2008

Price : $50

At a glance

  • Originator POZEN
  • Class Aminobenzoic acids; Antiemetics; Antimigraines; Antipyretics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Phenyl ethers; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 28 Nov 2005 Registered for Migraine in United Kingdom (PO)
  • 05 Aug 2005 Discontinued - Preregistration for Migraine in USA (PO)
  • 03 Mar 2005 A Committee on Safety of Medicines to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom agreed to advise the MHRA that the MAA be granted for naproxen sodium/metoclopramide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top